Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

By E. Castro, C. Goh, D. Olmos, E. Saunders, D. Leongamornlert, M. Tymrakiewicz, N. Mahmud, Tokhir Dadaev, K. Govindasami, M. Guy and 27 more. Journal of Clinical Oncology, 2013

785 citations recorded by the source corpus.

Subfields: Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/097e13d648945528d6a0c35f9887e2c59102b737

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. B. Kaufman
2. M. Friedlander
3. R. Shapira-Frommer
4. J. Balmaña
5. S. Domchek
6. Rita K Schmutzler
7. A. Hubert
8. O. Rosengarten

Citations in the corpus

• Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation (2014, background): “BRCA2-associated prostate cancer is more aggressive, with poorer survival.(16) For this reason, it is difficult to compare the response rate seen here with that of unselected prostate cancer, particularly given the small numbers.”
• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. (2020, neutral): “Diarrhea 55 (21) 2 (<1) 9 (7) 0 12 (14) 0”
• Olaparib for Metastatic Castration-Resistant Prostate Cancer. (2020, neutral): “Adverse event Any 244 (95) 130 (51) 114 (88) 49 (38) Anemia† 119 (46) 55 (21) 20 (15) 7 (5) Nausea 106 (41) 3 (1) 25 (19) 0 Fatigue or asthenia 105 (41) 7 (3) 42 (32) 7 (5) Decreased appetite 77 (30) 3 (1) 23 (18) 1 (<1) Diarrhea 54 (21) 2 (<1) 9 (7) 0 Vomiting 47 (18) 6 (2) 16 (12) 1 (<1) Constipat”